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Yosuke Ishitsuka1, Rei Watanabe1 and Manabu Fujimoto1
1 Dermatology, University of Tsukuba, Tsukuba, Ibaraki, Japan, 2 Dermatology, Tokyo Metropolitan Komagome Hospital, 
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The most widely accepted treatment for cutaneous angiosarcoma (CAS) is wide local 
excision and postoperative radiation to decrease the risk of recurrence. Positive surgical 
margins and large tumors (T2, >5  cm) are known to be associated with poor prog­
nosis. Moreover, T2 tumors are known to be associated with positive surgical margins. 
According to previous reports, the majority of CAS patients in Japan had T2 tumors, 
whereas less than half of the patients in the studies from western countries did so. 
Consequently, the reported 5­year overall survival of Japanese CAS patients without 
distant metastasis was only 9%, lower than that for stage­IV melanoma. For patients 
with T2 tumors, management of subclinical metastasis should be considered when plan­
ning the initial treatment. Several attempts to control subclinical metastasis have been 
reported, such as using adjuvant/neoadjuvant chemotherapy in addition to conventional 
surgery plus radiation. Unfortunately, those attempts did not show any clinical benefit. 
Besides surgery, new chemotherapeutic approaches for advanced CAS have been intro­
duced in the past couple of decades, such as paclitaxel and docetaxel. We proposed 
the use of chemoradiotherapy (CRT) using taxanes instead of surgery plus radiation for 
patients with T2 tumors without distant metastasis and showed a high response ratio 
with prolonged survival. However, this prolonged survival was seen only in patients who 
received maintenance chemotherapy after CRT, indicating that continuous chemother­
apy is mandatory to control subclinical residual tumors. With the recent development 
of targeted drugs for cancer, many potential drugs for CAS are now available. Given 
that CAS expresses a high level of vascular endothelial growth factor (VEGF) receptor, 
drugs that target VEGF signaling pathways such as anti­VEGF monoclonal antibody and 
tyrosine kinase inhibitors are also promising, and several successful treatments have 
been reported. Besides targeted drugs, several new cytotoxic anticancer drugs such 
as eribulin or trabectedin have also been shown to be effective for advanced sarcoma. 
However, most of the clinical trials did not include a sufficient number of CAS patients. 
Therefore, clinical trials focusing only on CAS should be performed to evaluate the effec­
tiveness of these new drugs.
Keywords: cutaneous angiosarcoma, concurrent chemoradiotherapy, maintenance chemotherapy, adjuvant 
chemotherapy, taxanes, eribulin, pazopanib, angiosarcoma of the scalp
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BACKGROUND
According to the Surveillance, Epidemiology, and End Results 
Program database, the number of patients with sarcoma 
recorded between 2010 and 2014 was only 1/100 of the num-
ber of patients with carcinoma in the same period. Moreover, 
angiosarcoma accounts for only 1% of all sarcomas, so patients 
with angiosarcoma constitute only 1 in 10,000 of all patients with 
malignant neoplasms (1–3). Although the incidence of angio-
sarcoma has increased in the past couple of decades, it is around 
0.5 per 1,000,000 persons, or fewer than 200 new patients, per 
year in the United States (3). Owing to this rarity, most previous 
publications have been case reports or small case series, mak-
ing it difficult to interpret the results because of the selection 
bias and small number of patients included in those studies. 
Furthermore, because of this rarity, no randomized phase-3 
study has been conducted, especially for angiosarcoma, and 
consequently, no clinical trial-proven standardized treatment 
has thus far been established. Although complete removal of the 
tumor was believed to be essential, as it is for other sarcomas 
(4, 5), some reports have suggested that wide-margin surgery 
will not deliver favorable results (6, 7). In this review, we will 
summarize the clinical features and current treatments of angio-
sarcoma and discuss the possibility of new therapeutic options 
for this rare disease.
CLiNiCAL PReSeNTATiON
Angiosarcoma develops in various soft tissues and organs, but 
the most commonly affected site is the skin [cutaneous angio-
sarcoma (CAS)] (8–10). According to an analysis of 434 cases of 
CAS, 62.1% of them developed in the head and neck, 24.4% in 
the trunk, 10.6% in the extremities, and 2.7% in other locations 
(11). CAS commonly occurs in the scalp and typically presents as 
an enlarging bruise-like purpura in the head and neck region and 
may be associated with ulceration and/or a tumor. Sometimes 
patients develop a thick blood crust. These head and neck CAS 
commonly develops in older men (12–14), whereas the second-
ary CAS, lymphedema-associated CAS [so-called Stewart-Treves 
syndrome (15)] and radiation-associated CAS (11, 16), usually 
develops within the lymphedema site and irradiated field >5 years 
after the surgery and radiation, respectively (12, 16).
Stewart-Treves syndrome was originally reported as lym-
phedema that developed after radical mastectomy and lymph 
node dissection (15), but in the past 15  years, we have never 
encountered Stewart-Treves syndrome that developed after the 
surgery for mammary carcinoma. Instead, in the same period, 
we experienced three cases of Stewart-Treves syndrome that 
developed in the lower limb after treatment for uterine carcinoma 
(17). This may be explained by the fact that the number of patients 
receiving conservative treatment for mammary carcinoma has 
increased, and as a consequence, the prevalence of Stewart-
Treves syndrome in the upper extremity has decreased (18). On 
the other hand, the occurrence of radiation-induced CAS in the 
breast is likely to increase given that the prognosis for mammary 
carcinoma is gradually improving and radiation is more often 
used to treat (16).
While the incidence of Stewart-Treves syndrome is not well 
known, it has been reported to be about 1/10 to 1/20 of all 
CAS (19–22). Similarly, the cumulative incidence of radiation-
associated CAS 15  years after radiotherapy for breast carci-
noma was reported to be 0.9 per 1,000 patients (23), meaning 
less than 1 occurrence per 10,000 irradiated patients per year. 
In this review, considering its rarity and etiological difference, 
we will focus mainly on primary CAS, the narrow sense of 
CAS (24).
Distant metastasis could occur within a month of primary 
surgery, but typically it occurs on average after a year (4, 5). 
The most common site of metastasis is the lung, followed by 
the lymph nodes, bone, and liver (4, 5, 25). Interestingly, lung 
metastasis often presents as pneumothorax, which may require 
urgent medication (26, 27).
DiAGNOSiS AND STAGiNG
Patients with typical presenting symptoms can be diagnosed clini-
cally, but the precise pathological diagnosis should be performed 
by an expert pathologist. The histologic features of angiosarcoma 
can vary between patients and even within the same patient. 
When the tissue specimens are taken from well-differentiated 
areas, the tumor cells usually form vessel-like structures and 
may be difficult to differentiate from normal vessels. However, 
the tumor vessels tend to form independent or separate networks 
with anastomoses (28). Other features such as cellular atypia, 
mitoses, and formation of multilayer endothelium can be helpful 
for diagnosis. On the other hand, in poorly differentiated areas, 
the tumor cells show sheet-like growth with hemorrhage and 
necrosis, which have fewer features than do vascular tumors. 
In such cases, positive staining for endothelial markers such as 
CD31, CD34, von Willbrand factor, and vascular endothelial 
growth factor (VEGF) are useful (29). Also, lymphatic endothelial 
markers such as D2-40 are positive for most superficial angiosar-
comas (28).
The staging of CAS is based on the TNM staging system 
of the American Joint Committee on Cancer (AJCC) (Table 1). 
The tumor grade based on the pathologic features is included in 
the staging. In brief, localized disease is classified as stage I or 
II; nodal spread or T2 tumor with histologic grade 3, as stage 
III; and distant disease, as stage IV. However, because there is no 
standardized treatment algorithm for each stage, staging of CAS 
has little clinical benefit in the treatment decision.
PROGNOSiS AND FACTORS ASSOCiATeD 
wiTH SURvivAL
Generally, soft-tissue sarcomas have a 50–60% survival rate (30), 
whereas the 5-year survival rate for angiosarcoma is <40% (12, 25, 
31, 32). Several factors are reportedly associated with poor 
survival: older age (25, 32), worse performance status (33, 34), 
larger tumor size (5, 8, 20, 32, 35–40), positive margin status 
(31, 32, 38, 41, 42), higher histologic type or grade (32, 37, 41, 
43, 44), scalp as the primary location (5, 36, 45), deeper location 
of the tumor (20, 31), and presence of distant metastasis (33, 38, 
TABLe 2 | Reported factors associated with poor survival determined by studies with >50 patients in CAS.
N Age Tumor size Pathological feature Margin Location Others
Albores­Saavedra et al. (11) 434 >50 N.S. Head and neck
Deeper location
Lymph node metastasis
Distant metastasis
Perez et al. (40) 88 N.S. >5 cm N.S.
Holden et al. (36) 72 N.S. >5 cm
>10 cm
N.S. N.S.
Guadagnolo et al. (5) 70 >5 cm
Satellitosis
N.S. Surgery alone
Patel et al. (25) 55 >70 N.S. N.S. N.S. Without multimodality  
or radiation therapy
N.S., not significant; PS, performance status.
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TABLe 1 | AJCC TNM staging system for soft tissue sarcoma.
 
 0 1 2  
T classification   Size<=5cm Size>5cm  
a: superficial tumor, b: deep tumor (divided by superficial fascia)  
N classification  
No nodal 
metastasis  
Nodal 
metastasis  
  
M classification  
No distant 
metastasis  
Distant 
metastasis  
  
Stage T N M Histologic grade  
I  
A 1a/b 
0 
0 
1 or not assessed 
B 2a/b 
II  
A 1a/b 2 or 3 
B 2a/b 2 
III  
2a/b 3 
Any  1 
Any  
IV  Any  Any  1 
Histologic grading is defined as follows: (1) Differentiation: score from 1 to 3, (2) Mitotic 
count: score from 1 to 3, and (3) Tumor necrosis: score from 0 to 2.
Sum (1) to (3) and determine grade as follows.
Gx: not assessed.
G1: total score of 2 or 3.
G2: total score of 4 or 5.
G3: total score of >5.
41, 46). On the other hand, the following factors were associ-
ated with favorable prognosis: surgery (20, 34), multimodal 
therapy (5, 39, 41) and postoperative radiotherapy (34, 36, 41, 43, 
47, 48). The studies that included more than 50 patients with 
CAS only are summarized in Table 2. According to these five 
studies, tumor size seems to be a consistently poor prognostic 
factor; indeed, patients with tumors larger than 10 cm all died 
of the disease (35, 36).
A study by Sinnamon et al. (32) of 821 angiosarcomas included 
211 cases of primary CAS in the head and neck. In their cohort, 
all cases of metastatic disease were excluded and all the patients 
received surgical treatment. They scored the following factors and 
classified the risk from low (total score 0–1), intermediate (total 
score 2–3), and high (total score 4–7): age > 70 as 1, black ethnicity 
as 1, histologic tumor grade 3 as 1, tumor size 3–7 cm as 1, tumor 
size larger than 7 cm as 2, microscopic residual tumor as 1, and 
macroscopic residual tumor as 2. By using this model, patients 
at high risk had a median overall survival of only 1.6 years with 
a hazard ratio of 5.65 when compared with patients at low risk. 
This result clearly indicates that these factors strongly correlate 
with poor survival.
Reports from Japan and from western countries showed 
differences in survival. In the study from Japan of 260 
cases of CAS, the 5-year overall survival among patients 
who could receive surgery was <20% (49) (median overall 
survival: < 20 months), whereas in the studies from western 
countries, it was 31–51% (5, 11, 25, 31, 40). CAS patients in 
Japan had equivalent survival to the “high risk” group reported 
by Sinnamon et  al. (32), with a median overall survival of 
1.6 years. This difference might be explained by the fact that the 
tumor size in Japanese patients is generally large: in the study 
of 260 CAS cases, 44% of the patients had tumors of at least 
10  cm (originally, described as tumors larger than 100  cm2) 
(49), whereas tumors larger than 5 cm (T2) constituted only 
18–38% of the patients in the studies from western countries 
(5, 11, 25, 40). Our multicenter study, which included only 
Japanese patients, was also T2 dominant: only 3 of 28 patients 
(11%) had a T1 tumor (19). In the meta-analysis by Hwang 
et al., which included 128 cases from seven studies (50), the 
median overall survival in the T1 group was significantly 
longer than that in the T2 group (31.4 months and 17.3 months, 
respectively: P <  0.001). Collectively, Japanese CAS patients 
have larger primary tumors than do CAS patients in western 
countries, and consequently, the survival of Japanese CAS 
patients is shorter.
TReATMeNT
Current Treatment Options
Surgery
Radical surgery with no residual tumor cell on the margin 
(R0 resection) is generally the primary goal of sarcoma treatment. 
In every review or set of guidelines, surgery with R0 resection is 
recommended as the goal of CAS treatment (28). In a system-
atic review by Shin et al. (51), absence of surgery was shown to 
correlate with poor survival; Trofymenko et  al. (52) reported 
similar result in a study using 764 cases of CAS extracted from 
the National Cancer Database in the United States. Therefore, 
there is little doubt that surgery is one of the best choice for the 
management of CAS.
TABLe 3 | Chemotherapy options and their effect for angiosarcoma.
Agent Patients N Response/median survival (months)
Anthracyclines Pooled analysis of 11 clinical trials for angiosarcoma from all sites
Young et al. (58)
108 Response ratio: 25% for all sites
PFS: 4.9, OS: 9.9
Paclitaxel Retrospective review of angiosarcoma from all sites
Italiano et al. (71)
34 Response ratio: 29.5% for all sites
68 Response ratio: 53% for all sites Response ratio: 78% for CAS
ANGIOTAX study: phase­2 study including angiosarcoma from all sites
Penel et al. (70)
30 Response ratio: 18% for all sites Response ratio: 89% for CAS
ANGIOTAX plus study: phase­2 study comparing paclitaxel with/without 
bevacizumab from all sites (showing paclitaxel arm only)
Ray­Coquard et al. (74)
24 Response ratio: 45.8% for all sites
PFS: 6.6, OS: 19.5
Retrospective study for head/neck CAS
Fata et al. (69)
9 Response ratio: 89% for CAS
Docetaxel Retrospective study for CAS
Nagano et al. (101)
9 Response ratio: 67% for CAS
Gemcitabine Retrospective study with angiosarcoma from all sites
Stacchiotti et al. (76)
25 Response ratio: 64% for all sites
PFS: 7, OS: 17
PFS, progression-free survival; OS, overall survival; CAS, cutaneous angiosarcoma.
suggested the use of minimal surgery as part of the management 
of CAS (6, 56), such as for those cases with a diffuse lesion pattern 
involving vital structures, recurrent disease, or metastasis.
Chemotherapy
The chemotherapeutic options currently available for angiosar-
coma are listed in Table 3. Chemotherapy using anthracyclines 
alone or in combination with ifosfamide have been used for 
unresectable and metastatic angiosarcoma (35, 57, 58). However, 
anthracyclines have cardiac toxicity which make it difficult to 
apply in older patients. Taxanes, which inhibit tubulin elonga-
tion, were introduced in the 1990s as a novel cytotoxic drug 
and have become accepted as standardized treatment options 
in various kinds of cancers such as those of the breast (59), lung 
(60), stomach (61), and uterus (62), because of their high effi-
cacy. Although several clinical studies have shown that taxanes 
are of little benefit for sarcomas (63, 64), the angiosarcomas 
included in those clinical studies showed antitumor activity 
(64). Taxanes not only have a direct antitumor effect but also 
have been shown to exert an antiangiogenic effect (65, 66), 
which is thought to be suitable for the treatment of vascular 
tumors. Indeed, taxanes were shown to be effective for the treat-
ment of Kaposi sarcoma (67, 68).
In 1999, Fata et al. (69) achieved a response ratio of 89% by 
using paclitaxel monotherapy for the treatment of head and neck 
CAS. Later, Penel et al. (70) conducted the first phase-2 trial for 
metastatic or locally advanced angiosarcoma, which included 30 
patients treated with paclitaxel. In that clinical trial, the progres-
sion-free survival rate after 4 months was 45%, and the median 
overall survival was 8 months. Considering that the patients with 
distant metastasis consisted of 74% of the study population and 
36% of them had had previous systemic chemotherapy, this result 
was encouraging. Italiano et al. (71) showed, albeit in a retrospec-
tive study, that paclitaxel achieved an equivalent outcome to that 
of anthracyclines in the treatment of advanced angiosarcoma 
despite the patients treated with paclitaxel being a decade older 
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Although no standardized treatment recommendation has 
been established, a margin of less than 1 cm is associated with 
poor survival (49). The depth of the resection has not been 
well discussed, but generally if the tumor does not extend into 
the deep fascia, a resection layer including the deep fascia is 
adequate. If the tumor directly invades into the deep fascia, 
removal of the underlying structures, e.g., the periosteum 
or even the outer shell of the skull, is required to obtain R0 
resection.
Unfortunately, it is common to see positive microscopic (R1) 
or macroscopic (R2) margins even after a wide surgical margin 
from the visible tumor border has been obtained (4, 8, 31, 
36, 41). Pawlik et  al. (4) reported that in their series of 29 
patients, 18 (62.1%) had an initial diagnosis of T1 (<5  cm) 
tumor, but 11 of those tumors turned out to be T2 (>5  cm) 
after surgical pathology evaluation of the resected tumor. The 
clinical margin of the tumor in CAS is difficult to determine 
because it often develops as a multifocal tumor and presents 
as a skip lesion. Moreover, when CAS develops near important 
structures such as the eye, surgical removal with an adequate 
margin is impossible. As a consequence, the rate of local recur-
rence after treatment is high reportedly ranging from 26 to 
100% (5, 9, 25, 41). Lahat et  al. (53) reported 32 of 44 cases 
of locally recurrent angiosarcoma treated with surgery, 70% of 
which achieved complete removal of the recurrent tumor, with 
a 5-year overall survival of 44%.
To reduce local recurrence, postoperative radiotherapy 
covering a wide area with a >50 Gy dose has been reported by 
several studies to be effective not only for local control but also 
for overall survival (4, 5). Currently, wide local excision followed 
by radiation is the most accepted treatment for CAS (28, 54, 55); 
however, despite such mutilating multimodal treatment, survival 
of patients, especially of those with large tumors, is still unsatis-
factory (19, 32).
Other than radical surgery, palliative surgery might have role in 
patients with large tumors to reduce the tumor load. Some reports 
5Fujisawa et al. New Treatment Options for CAS
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than those treated with anthracyclines (67.4 and 57.4 years old, 
respectively). Collectively, taxanes can achieve a similar level 
of antitumor effect to that achieved by anthracyclines, but with 
less toxicity, and therefore, a recent report (72) suggested using 
taxanes as the first-line treatment for CAS with unresectable or 
distant disease. Indeed, we reported (17, 73) successful treatment 
results using taxanes as the first-line therapy for primary CAS.
Because both taxanes have been reported to be effective, 
the decision about which taxane to use as the first-line might 
be difficult. In this review, we recommend paclitaxel as the 
first-line treatment since paclitaxel has been evaluated in dif-
ferent phase-2 studies (70, 74), whereas docetaxel has not yet 
been evaluated in a prospective study. However, docetaxel still 
has a role as a second-line therapy in patients refractory to 
paclitaxel (75).
Gemcitabine has been reported to be effective for sarcomas 
both as a single agent (76, 77) and in combination with docetaxel 
(78, 79). Several case series (77, 80) have been reported in which 
gemcitabine for the treatment of angiosarcoma was used with 
favorable outcomes. Moreover, albeit in a study based on a ret-
rospective pooled analysis (76), gemcitabine showed an overall 
response rate of up to 68% for angiosarcoma (76). If this agent 
is used as monotherapy, the toxicity profile is better than that of 
anthracyclines but still has a significant incidence of bone mar-
row suppression.
Radiation
Radiation is usually delivered after surgery for better local con-
trol (28, 54, 55). However, dismal outcome have been reported 
when radiation was used as monotherapy (5, 38, 43). Therefore, 
radiation monotherapy is generally used for palliation, not for 
curative intent because of frequent recurrence, as high as 100% 
in previous studies (25, 36, 42, 43). On the other hand, Ogawa 
et al. (34) reported that in their cohort of 25 patients who received 
radiation monotherapy with curative intent, 11 of the 14 patients 
(79%) who received >70Gy achieved local control, whereas only 
3 of the 11 patients (27%) who received <70  Gy did. A study 
by Scott et al. (81) of 41 patients treated with radiation recom-
mended at least 60–65 Gy for the postoperative tumor bed and 
70–75 Gy for patients who receive radiation monotherapy. Others 
(82) suggested that improved delivery of radiation might achieve 
higher efficacy. Since no prospective study has been conducted 
to evaluate the role of radiation as the first-line therapy, radiation 
monotherapy is still difficult to use as curative intent therapy 
for primary disease. We will discuss combination radiation and 
chemotherapy in the next section.
New Treatment Options
Chemoradiotherapy (CRT)
The use of chemotherapy and radiation (CRT) concurrently or 
concomitantly is one of the standardized treatment methods for 
several cancers: esophageal (83), head and neck (84), rectal (85), 
and cervical (86). Chemotherapeutic agents such as 5-fluoro-
uracil (84, 85), cisplatin (87), gemcitabine (88), and taxanes 
(89, 90) are expected to act not only as cytotoxic but also as 
radiosensitizing agents. Therefore, CRT may sometimes cause 
higher toxicity than does monotherapy but can be justified by 
its high antitumor effect, and in most cases, such side effects are 
manageable. Besides, although many cancer treatments intro-
duced CRT as one of the key treatments, it was an uncommon 
method among cutaneous malignancies. In such a situation, 
we started to use cisplatin and 5-fluorouracil concurrently 
with radiation for the management of unresectable/metastatic 
cutaneous squamous cell carcinoma with the same protocol 
used in the head and neck and reported successful treatment 
results (91–93).
As described previously, a Japanese retrospective study of 
CAS (49) revealed that the median overall survival of patients 
with non-metastatic localized CAS who received surgery was 
less than 20 months, but this finding was not surprising because 
we have reported a similar dismal outcome (13.5 months) (19). 
We suspected that increased expression of VEGF during the 
wound healing process (94) caused by mutilating surgery might 
cause progression of residual angiosarcoma because angiosar-
coma has been reported to express a VEGF receptor (95–97). 
As discussed in the previous section, tumor size is the most com-
mon factor for poor prognosis, which is commonly related to a 
positive surgical margin. Therefore, it is convincing to consider 
that such subclinical residual tumors could be expanded by VEGF 
released by surgery.
In such a situation, a retrospective study (47) of use of chemo-
therapy (anthracyclines) and radiation for five head and neck 
CAS (four scalp and one lip, three of them with high-grade 
tumors) was reported and achieved a median overall survival of 
27.0  months, which was better than the reported median sur-
vival of face and scalp CAS (<20 months) (6, 36, 45). However, 
there was a concern related to use of anthracyclines for older 
CAS patients for whom the drug might not be tolerable. On the 
other hand, taxanes have a better toxicity profile, and therefore, 
we expected that older CAS patients could tolerate it. Moreover, 
taxanes are known as radiosensitizers (89, 90), and therefore, 
possibly an ideal agent for CRT for the treatment of CAS.
The reported cases of CAS treated with CRT are described in 
Table 4. Because the study by Mark et al. (47) did not describe 
the timing of the chemotherapy, we could not determine whether 
they used chemotherapy concurrently or concomitantly with 
radiation. In the study by Miki et  al. (98), 5 of the 12 patients 
who received docetaxel, the schedule was adjusted so that the 
drug was administered concurrently only on the first and last 
weeks of radiation. Another seven patients received docetaxel 
for 2–6 weeks during radiation in accordance with patient status. 
All the patients in the other two studies received chemotherapy 
and radiation concurrently (19, 98, 99). Most of the arms are 
composed of scalp CAS, which correlated with poor survival. The 
response to CRT was 82% (98) and 94% (19), with a statistically 
higher median overall survival than that of surgery followed by 
radiation in both studies. Representative photographs of patients 
who received CRT are presented in Figures 1A–D.
Concurrent CRT brings severe side effects than when each 
treatment is delivered as monotherapy. In our study, 78% of 
the patients who received concurrent CRT had CTCAE grade-4 
neutropenia, but the neutropenia was made manageable by 
use of granulocyte-colony stimulating factor and no treated-
related death was observed (19). In the study by Miki et  al. 
TABLe 4 | Study using chemotherapy and radiation therapy for CAS.
Study N Patients tumor location/size Treatment RT dose Response/pattern of failure Median OS (months)
Mark et al. (47) 5 Scalp: 4 and Face: 1
Size not described
Anthracyclines 30–76.2 Gy Response ratio: N.D.
Local: 2/5
Distant: 2/5
27.0
4 Scalp: 1 and Face: 3
Size not described
Surgery 50–65 Gy Local: 1/4
Distant: 0/4
Not reached
Rhomberg et al. (99) 1 Scalp/face: 1
T2
Razoxane
Vindesine
35–66 Gy CR
Alive without failure
41
Miki et al. (98) 11
Scalp: 16 and Face: 1
T1: 1 and T2: 15
Docetaxel 70 Gy Response ratio: 82%
Local: 4
Distant: 5
Both: 4
33.7
]*
5 Surgery/IL-2 22.7
Our study (19) 16
Scalp: 14, and Extremity: 2
T1: 2 and T2: 14
Docetaxel
<65Gy:12
≧65Gy:16
Response ratio: 94%
Local: 6
Distant: 7
Not reached
]**
12 Scalp: 10, extremity: 2
T1: 2 and T2: 10
Surgery Only 1 patient still alive 15.0
*P < 0.05.
**P < 0.01.
OS, overall survival; CAS, cutaneous angiosarcoma; N.D., not described; IL-2: interleukin-2.
6
Fujisawa et al. New Treatment Options for CAS
Frontiers in Oncology | www.frontiersin.org March 2018 | Volume 8 | Article 46
(98), all the patients developed grade 1–3 dermatitis but healed 
uneventfully.
Taking these finding together, CRT using taxanes could 
achieve satisfactory antitumor activity with good tolerability 
and might bring better survival than does conventional surgery 
followed by radiation especially for CAS of the scalp. Although 
the use of taxanes concurrently might bring severe side effects, 
we suggest concurrent CRT to gain maximum antitumor effect as 
long as the side effects are tolerable and manageable.
Maintenance Chemotherapy
To prevent locoregional and distant failure after response to 
chemotherapy, some previous report continued chemotherapy 
to maintain the response. Gambini et al. (100) achieved complete 
remission of radiation-induced angiosarcoma after treatment 
with paclitaxel and maintained the response for 4  years by 
maintenance therapy with intervals of no longer than 3 weeks. 
Interestingly, they had local recurrence twice when the treatment 
was delayed, but in both instances, a new complete remission 
was rapidly achieved with the same treatment and the patients 
remained disease-free at the time of their report. Nagano et al. 
(101) reported nine CAS patients treated with docetaxel, eight 
of whom continued docetaxel for 3–22 months (Table 5). None 
of the patients developed distant metastasis during maintenance 
chemotherapy. Rhomberg et al. (99) treated nine patients with 
angiosarcoma (five with thyroid, one with left ventricle, one with 
bladder, and one with scalp/face) with concurrent CRT using 
razoxane and vindesine. Complete remission of the tumor was 
obtained in six patients, five of whom received maintenance 
chemotherapy for 6 weeks to a year. Of those five patients, two 
developed recurrence but only one developed it during the 
maintenance chemotherapy.
In our study (19), 16 CAS patients were treated with concur-
rent CRT and 9 of them received maintenance chemotherapy. 
Locoregional relapse was seen in three of the nine patients who 
received maintenance chemotherapy, whereas it was seen in 
four of the seven patients who did not receive it. On the other 
hand, only two of the nine patients who received maintenance 
TABLe 5 | Maintenance chemotherapy after primary therapy.
Study N Tumor location Primary 
chemotherapy
RT dose Maintenance 
chemotherapy and duration 
(months)
Pattern  
of failure
Median OS 
(months)
Nagano et al., 2007 (101) 9 Scalp: 6, Face: 1
Neck: 1, Leg: 1
Docetaxel – Docetaxel 3–22
MD: 13.5
Local: 4
Distant: 0
Not described
Rhomberg et al. 2009 (99) 5 Thyroid: 4, Scalp/
face: 1
Razoxane
Vindesine
35–66 Gy
MD: 56 Gy
Razoxane
Vindesine
6 weeks­36
MD: 12
Local or  
distant: 2
27.0
Our study
2014
9 Scalp: 7, Limb: 2
Docetaxel
48–80 Gy
MD: 70 Gy
Docetaxel 3–50
MD: 12.5
Local/LN: 3
Distant: 2
Not reached
]**
7 Scalp: 7 52.5–70.4 Gy
MD: 70 Gy
Not done Local: 4
Distant: 5
21.0
** P < 0.01.
RT, radiotherapy; MD, median; OS, overall survival.
FiGURe 1 | Representative cases of CAS treated by concurrent CRT.
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chemotherapy developed distant metastasis, whereas five of the 
seven patients who did not receive maintenance chemotherapy 
did develop distant metastasis (P <  0.05). A study by Ito et al. 
(75) showed that 19 patients who received maintenance chemo-
therapy using taxanes had significantly better survival than did 24 
patients who received maintenance chemotherapy without taxa-
nes (P < 0.0024) Collectively, maintenance chemotherapy after 
remission obtained by CRT seems to suppress tumor regrowth 
and development of distant metastasis. However, there is no 
consensus as to how long this maintenance chemotherapy should 
be continue. Further investigation is needed to determine the 
optimal length of maintenance chemotherapy.
Adjuvant/Neoadjuvant Chemotherapy
The use of adjuvant chemotherapy after complete removal of the 
tumor is attractive because we experience many CAS patient who 
develop distant metastasis even though there is no locoregional 
failure. However, anthracycline-based adjuvant chemotherapy 
did not show any survival benefit in soft tissue sarcomas (102). 
Indeed, we could not see any survival benefit in CAS patients by 
using taxanes after surgery and radiation (7). Similarly, adjuvant 
chemotherapy did not show a clear benefit among angiosarcoma 
patients treated with anthracyclines, paclitaxel, and other com-
binations (5, 6, 41, 44).
Some groups reported the use of chemotherapy before surgery 
(neoadjuvant chemotherapy) but did not show any survival 
benefit in face CAS (103) or in head and neck CAS (5). However, 
a certain percentage of patients who received neoadjuvant 
chemotherapy could achieve a complete response (60% in face 
CAS (103)) and did not require definitive surgery. Thus, the effect 
of neoadjuvant chemotherapy is difficult to interpret.
Since no large prospective study has been conducted to 
evaluate the value of adjuvant and neoadjuvant chemotherapy, 
those previous studies should be read with caution. However, 
the largest retrospective analysis of CAS including 821 patients 
indicated that both adjuvant and neoadjuvant therapy after 
surgery did not show any survival benefit on univariate and 
multivariate analyses (32). Further prospective study is required 
to evaluate the role of adjuvant/neoadjuvant chemotherapy 
for CAS.
New Drugs
Anti-VEGF Drugs
Angiosarcomas express VEGFR (95, 97, 104), and overexpres-
sion of VEGF converted slow-growing vascular endothelial 
tumors to fast-growing malignant tumors in a mouse model and 
formed invasive angiosarcoma in immunodeficient mice (105). 
Conversely, blockade of the VEGF/VEGFR pathway inhibited 
tumor growth in  vitro (106). Therefore, it is reasonable for 
the treatment to target the VEGF/VEGFR signaling pathway. 
Several studies using anti-VEGF monoclonal antibody (beva-
cizumab) have shown antitumor activity in angiosarcomas: 4 
of 30 patients treated with bevacizumab had a partial response, 
with a mean time to progression of 26 weeks (107), and 2 of 2 
patients treated with bevacizumab and radiation had a complete 
response (108).
On the basis of this background, Ray-Coquard et al. (74) con-
ducted a non-comparative, open-label, randomized phase-2 trial 
to explore the activity and safety of bevacizumab and paclitaxel 
therapy for patients with advanced angiosarcoma. Fifty patients 
were randomized and assigned to two arms: (1) the paclitaxel 
alone or (2) the paclitaxel and bevacizumab arm. From the 
findings, they concluded that there is no benefit from adding 
bevacizumab to paclitaxel (median overall survival: 19.5 versus 
15.9 months).
Other than monoclonal antibody, two small-molecule multi- 
tyrosine kinase inhibitors that can inhibit the VEGF/VEGFR 
signaling pathway have been used for the treatment of angiosar-
coma patients: sorafenib (109) and pazopanib (110). A phase-2 
trial including 37 patients with recurrent or metastatic angiosar-
coma treated with sorafenib showed a response ratio of 14% with 
median progression-free survival of 3.8 months (111). No clinical 
trial to evaluate pazopanib activity in angiosarcoma has been 
conducted. In a case series using pazopanib for the treatment 
of taxane-resistant CAS, two of five patients achieved a partial 
response with median progression-free survival of 94 days (112). 
On the other hand, a case series of eight CAS patients treated with 
pazopanib did not show any benefit (113). Although we do not 
have enough conclusive evidence, the current first-line treatment 
should still be taxanes and anti-VEGF pathway therapy should be 
considered as the second- and third-line therapy.
Eribulin Mesylate
Eribulin mesylate suppresses microtubule polymerization and 
sequesters tubulin into nonfunctional aggregates, which is a 
mechanism distinct from those of other tubulin-targeting drugs 
such as taxanes (114). A phase-3 study comparing dacarbazine 
and eribulin in patients with advanced liposarcoma or leiomyo-
sarcoma showed improved survival in patients treated with eribu-
lin (115). This phase-3 study did not include angiosarcoma, and 
therefore, we do not have any evidence on the effect of eribulin for 
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taxanes when we encounter CAS of the scalp with a T2 tumor. We 
also recommend maintenance chemotherapy even if complete 
remission of the tumor has been achieved. On the other hand, for 
T1 CAS with a clear tumor border, the current standard surgery 
followed by radiation might be sufficient to obtain a successful 
result. However, these recommendations are based on a small 
number of retrospective studies. CRT and maintenance chemo-
therapy should be evaluated with prospective clinical studies to 
confirm the superiority of this strategy.
Moreover, we currently do not have many options for when the 
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treatment after taxane-failure. Several clinical studies are now 
ongoing or planned to evaluate the effect of multi-kinase inhibi-
tors such as sorafenib or pazopanib (clinicaltrials.gov). We hope 
the treatment of CAS will be dramatically improved, as it has for 
melanoma, in the near future.
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